“The continued development of ELI-002 is supported by encouraging clinical results that have demonstrated a favorable safety profile, a strong correlation between T-cell response, tumor biomarker reductions and reduced risk of recurrence or death.” REFERENCES: Elicio Therapeutics reaches alignment with...
[7]https://www.kcl.ac.uk/news/mrna-cancer-vaccine-potential-advanced-stage-cancer-patients-in-phase-1-trial [8]https://oncologypro.esmo.org/meeting-resources/esmo-congress-2024/first-in-human-phase-i-ii-monotherapy-dose-escalation-study-of-mrna-4359-an-mrna-encoded-pd-l1-ido1-antigen-spec...
A Phase 1/2 clinical trial investigating a new 7 peptide formulation, ELI-002 7P (G12D, R, V, A, C, S, G13D; NCT NCT05726864), is currently in progress. Trial Registration NCT04853017 Ethics Approval The study was approved by the local institutional review board at each study site ...
presented updated preliminary results from the ongoing AMPLIFY-7P Phase 1 clinical trial (NCT05726864) of ELI-002, an Amphiphile (“AMP”) cancer vaccine
Phase 2 trial of ELI-002 monotherapy in pancreatic ductal adenocarcinoma (“PDAC”) planned to initiate in early 2024 BOSTON, Jan. 09, 2024 (GLOBE NEWSWIRE) --Elicio TherapeuticsInc. (Nasdaq: ELTX, “Elicio Therapeutics”...
Dr Barragan-Carrillo on Global Disparities in Clinical Trial Availability in RCC Dr Abaza on Addressing the Need for Additional Targeted Therapies in AML/MDS Dr Garfall on the Potential Role for Consolidation or Maintenance CAR T-Cell Therapy in ...
The randomized phase II is now open in patients with pancreas cancer.Clinical trial information: NCT05726864.ELI-002 Amph-Peptides 7P Dose1.4 mg4.9 mg (RP2D)mKRAS6/ DDDDV 13D8/ DDDDRVVVSafety (DLT)^0/60/8Median T cell fold change*9.3109.2Biomarker Response#2/5 (40%)5/7 (71%)^...
A randomized Phase 2 clinical trial (NCT05726864) investigating a 7-peptide formulation (G12D, R, V, A, C, S, G13D) is underway.James R. PerryHaley VanWykAmy M. TavaresThian KheohEsther WelkowskyChristopher M. HaqqPeter C. DeMuth...
An interim analysis is planned using group sequential design for control of overall alpha 0.10.Clinical trial information: NCT05726864.Zev A. WainbergUCLA School of Medicine, Los Angeles, CAVincent ChungCity of Hope, Duarte, CACraig E. Devoe...